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background:  Reoperation for mitral valve bioprosthetic deterioration is associated with significant morbidity and mortality. With 
improvements in technology and imaging, transcatheter techniques are utilized as alternative strategy in high-risk individuals. We report our 
experience of completely percutaneous transseptal-transapical mitral valve-in-valve (ViV) implantation using fusion imaging.
methods:  Between February 2012-June 2014, 14 patients (age 71±14 years, 7 female, 5 male) presented to our institution with severe 
mitral bioprosthetic (range 25 to 33 mm) dysfunction at a median of 3302 days [IQR: 2503 to 3565] following surgery. Mode of prosthesis 
failure was severe regurgitation in 7.1%, stenosis in 57.1%, and combined in 21.4%. Risk scores predicted a 30-day mortality of 
13.1±11.0% (EuroSCORE II) and 14.1±11.7% (STS). All individuals had preoperative TTE and cardiac CT performed and were evaluated 
by our multidisciplinary heart team. Percutaneous transseptal and transapical access were performed with creation of an arteriovenous 
rail for percutaneous delivery via transfemoral approach. At the time of the intervention, fusion imaging using the HeartNavigator and 
EchoNavigator systems were employed.
results:  Complete percutaneous mitral ViV implantation was successfully performed in 12/14 (85.7%) patients. In 10 patients, a Medtronic 
Melody valve was implanted. The remaining 4 patients received an Edwards Sapien (23mm,2; 26mm,2) valve. There were 2 intra-
operative complications: a valve embolization and a tension pneumothorax, both leading to hemodynamic collapse and subsequent intra-
procedural and post-operative (day 8) mortality, respectively. The mean NYHA functional class improved from 3.2±0.6 to 1.1±0.8 (p≤0.01) 
over a median follow of 173 days (IQR:13.5 to 330).The mean transvalvular gradient improved from 11.6±4.3 to 5.1±2.7 (p<0.01) after 
implantation with all patients having mild or no residual regurgitation.
Conclusion:  In high-risk patients, completely percutaneous transseptal-transapical mitral ViV implantation is a promising therapeutic 
option in individuals with degenerated bioprostheses that is associated with a favorable outcome.
